HIGHLIGHTS
SUMMARY
To further improve understanding and anti-tumor activity of HER2-specific CAR-T_cells, additional preclinical, in_vitro experiments compared the efficacy of trastuzumab vs. trastuzumab-derived CAR-T_cells. Inhibition of the Transforming Growth_Factor-beta-1 (TGF-β1) pathway has been shown to block the EMT process in cancer cells in_vitro, and, consequently, to restore the cytotoxic activity of HER2-specific CAR-T_cells. TGF-β1 inhibitors showed some promising activity in enhancing the killing capacity of HER2-CAR-T_cells also in_vivo, in a mouse model, and represent an attractive field of investigation. PD-1 blockade has . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.